about
Emerging drugs for uveitisPars Planitis: Epidemiology, Clinical Characteristics, Management and Visual PrognosisSystemic Treatment of Pediatric Psoriasis: A ReviewAnti-TNF therapy for juvenile idiopathic arthritis-related uveitisThe Future Is Now: Biologics for Non-Infectious Pediatric Anterior UveitisProfile of adalimumab and its potential in the treatment of uveitisTreatment of Juvenile Idiopathic Arthritis-Associated UveitisUveitis in juvenile idiopathic arthritisEfficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case seriesReview of Systemic Immunosuppression for Autoimmune UveitisControversies in juvenile idiopathic arthritis-associated uveitis.The development and assessment of biological treatments for children.Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.Aqueous Humor Levels of Different Interleukins 1-β, 2, 6 and 10, Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab.Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up.Biological response modifier therapy for refractory childhood uveitis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina.Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.Autoantibody production in anti-TNF-alpha-treated patients.Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Prevention and management of cataracts in children with juvenile idiopathic arthritis-associated uveitisDisease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.Adalimumab for Ocular Inflammation.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Pediatric uveitis: An update.A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions.Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Pharmacotherapy of uveitis.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Adalimumab (humira™) in ophthalmology: a review of the literature.Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.Biological agents for the treatment of uveitis.
P2860
Q24630848-D8F4DEF7-305E-44EA-B0FB-6D037A142084Q26751204-80C37135-C334-4D7E-87E4-16795673FCEAQ26753026-5669EABD-123A-4F29-A22F-581B94769D15Q26849811-11D77060-E47C-4E10-A2DB-B24DF5C8F319Q27025862-449D782C-8205-4583-A683-571BBEB14B37Q28077781-7D0F7C33-A0DD-4D45-8394-93266F71EAAAQ28080084-962E5953-4CB7-4F89-98D6-806E3CDF9F4FQ28086972-67C61C2D-52EA-4F10-A2FD-5C65F8BDE457Q33712570-76853EF8-9D2C-4519-85D9-994EAF509D67Q34627012-371254AB-FB38-4DA2-B000-7F97F28B5ED0Q34742968-E66424EF-C842-4505-BDD2-802621748A92Q35135936-9DE77BF1-A7EF-41C3-81B4-313F717730F5Q35150941-5F547BB7-392A-403E-8087-78865E45C180Q35584483-42DC4CB1-6D81-48AE-9BAD-E66B301BEBECQ35825121-0C051521-85B0-484F-A069-3625FA483C8BQ36025876-BB50E321-0E40-4E8C-A779-3DC2191ABDB3Q36171750-E073CD65-EA8A-412B-9586-38B48773F5D6Q36846629-6C45F6BA-7C3A-45BC-9351-F50A67B4E3F4Q36849136-A1A55065-30E5-4736-9EEA-D19CECECB4E4Q36958337-0B57BA14-F455-4814-A1E0-3953368DA9C9Q37105146-1DFBF8F4-5DD6-4B64-AB43-4E9CFB770E43Q37115017-20A81F18-3E1D-423F-BC55-52129A7FC321Q37147226-A9E9986C-AEAF-4B5E-B5D0-7C2353CFE6A5Q37276953-87E7DED6-1024-472A-B253-347F25AEBD0FQ37290665-7858DD49-DD73-4B29-9C26-4E4617E042CAQ37413687-4508C196-79FD-4040-B1A5-92ED191D7D9BQ37479820-3669C3BA-7D0A-4B1E-80BC-43AE9B848217Q37482393-F2B9E32D-10B9-4CE0-B559-C736B37EE627Q37561994-6D765B7D-5155-4BE1-B654-A4ED3DE2473FQ37600483-4E93339F-28FC-43C5-B863-80D7AF861E1DQ37650221-17909536-ACA1-42BB-BB14-10F349B9BD5BQ37724245-DF592FE8-DFDD-455C-85BA-241202ED95EBQ37756167-0204293D-0240-4EAB-BD4C-2B589300F026Q37797940-5C513506-73F8-4EDC-A415-484CE2039737Q37820898-3CD17CA4-71C4-421C-983B-16CA0DBD742BQ37823308-834087A3-196C-4E9E-B85D-C5A5D5A968D9Q37834466-5CC13EAA-E90F-486A-97F4-3092E435B597Q37936394-8A1D1E42-62E3-4163-BECD-A1ED1BBF189EQ37956187-35284A62-ADD9-4D0F-930C-6F4B387694E0Q37984565-4ED6FC46-A265-4D8D-8C89-10B7569A9BE0
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Adalimumab in the therapy of uveitis in childhood
@ast
Adalimumab in the therapy of uveitis in childhood
@en
type
label
Adalimumab in the therapy of uveitis in childhood
@ast
Adalimumab in the therapy of uveitis in childhood
@en
prefLabel
Adalimumab in the therapy of uveitis in childhood
@ast
Adalimumab in the therapy of uveitis in childhood
@en
P2093
P2860
P356
P1476
Adalimumab in the therapy of uveitis in childhood
@en
P2093
Christoph Deuter
Deshka Doycheva
Hartmut Michels
Jasmin Kuemmerle-Deschner
Manfred Zierhut
Renate Haefner
Sabine Biester
P2860
P304
P356
10.1136/BJO.2006.103721
P407
P577
2006-10-11T00:00:00Z